scholarly journals Safety and efficacy of B-domain truncated recombinant factor VIII in previously treated patients with hemophilia A: Comparison of data between total population and Japanese subject population

2014 ◽  
Vol 25 (1) ◽  
pp. 75-81
Author(s):  
Takashi SUZUKI ◽  
Midori SHIMA ◽  
Hideki UCHIUMI ◽  
Kazuo KAWASUGI ◽  
Yoichi SAKATA ◽  
...  
1997 ◽  
Vol 78 (05) ◽  
pp. 1352-1356 ◽  
Author(s):  
Emel Aygören-Pürsün ◽  
Inge Scharrer ◽  

SummaryIn this open multicenter study the safety and efficacy of recombinant factor VIII (rFVIII) was assessed in 39 previously treated patients with hemophilia A (factor VIII basal activity ≤15%).Recombinant FVIII was administered for prophylaxis and treatment of bleeding episodes and for surgical procedures. A total of 3679 infusions of rFVIII were given. Efficacy of rFVIII as assessed by subjective evaluation of response to infusion and mean annual consumption of rFVIII was comparable to that of plasma derived FVIII concentrates. The incremental recovery of FVIII (2.4 ± 0,83%/IU/kg, 2.12 ± 0.61%/IU/kg, resp.) was within the expected range. No clinical significant FVIII inhibitor was detected in this trial. Five of 16 susceptible patients showed a seroconversion for parvovirus B19. However, the results are ambiguous in two cases and might be explained otherwise in one further case. Thus, in two patients a reliable seroconversion for parvovirus B19 was observed.


Sign in / Sign up

Export Citation Format

Share Document